BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Open Access
- 29 January 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 16
Abstract
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell-based disorders characterized by ineffective hematopoiesis, increased genomic instability and a tendency to progress toward acute myeloid leukemia (AML). MDS and AML cells present genetic and epigenetic abnormalities and, due to the heterogeneity of these molecular alterations, the current treatment options remain unsatisfactory. Hypomethylating agents (HMA), especially azacitidine, are the mainstay of treatment for high-risk MDS patients and HMA are used in treating elderly AML. The aim of this study was to investigate the potential role of the epigenetic reader bromodomain-containing protein-4 (BRD4) in MDS and AML patients. We identified the upregulation of the short variant BRD4 in MDS and AML patients, which was associated with a worse outcome of MDS. Furthermore, the inhibition of BRD4 in vitro with JQ1 or shRNA induced leukemia cell apoptosis, especially when combined to azacitidine, and triggered the activation of the DNA damage response pathway. JQ1 and AZD6738 (a specific ATR inhibitor) also synergized to induce apoptosis in leukemia cells. Our results indicate that the BRD4-dependent transcriptional program is a defective pathway in MDS and AML pathogenesis and its inhibition induces apoptosis of leukemia cells, which is enhanced in combination with HMA or an ATR inhibitor.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo
This publication has 40 references indexed in Scilit:
- Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemiasLeukemia Research, 2017
- Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid LeukaemiaDrugs, 2016
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- Genomic landscape of CD34 + hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markersProceedings of the National Academy of Sciences, 2014
- Stem cell origin of myelodysplastic syndromesOncogene, 2013
- Epigenetics of myelodysplastic syndromesLeukemia, 2013
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- Myelodysplastic syndrome: An inability to appropriately respond to damaged DNA?Experimental Hematology, 2013
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patientsEuropean Journal of Haematology, 2005